Search...
Jincheng Pharm: Subsidiary products are expected to be selected for the 11th batch of national centralized drug procurement
On October 28th, Jincheng Pharm announced that its wholly-owned subsidiary Beijing Jincheng Taier Pharmaceutical Co., Ltd. and its holding subsidiary Guangdong Jincheng Jinsu Pharmaceutical Co., Ltd. participated in the bidding for the 11th batch of national centralized drug procurement organized by the National Organization for Drug Centralized Procurement and Use Joint Procurement Office. Jincheng Taier's Rebapamide Tablets and Jincheng Jinsu's Cefazolin Sodium for Injection are expected to be selected in this centralized procurement
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments